Nona and Lonza Forge Alliance to Breach the Brain's Final Frontier

CAMBRIDGE, MA & BASEL, SWITZERLAND – July 02, 2026 – In a move that could reshape the landscape of neurological medicine, biotechnology innovator Nona Biosciences and manufacturing giant Lonza have entered a strategic collaboration. Their shared goal is to conquer one of drug development's most formidable obstacles: the blood-brain barrier (BBB). The partnership aims to create a best-in-class delivery system using single-domain antibodies, potentially unlocking a new generation of therapies for devastating central nervous system (CNS) diseases like Alzheimer's and Parkinson's.

The alliance combines Nona's cutting-edge antibody discovery platform with Lonza's world-class development and manufacturing capabilities. Under the agreement, Nona will receive upfront and option payments, with both companies sharing revenue from future licensing deals—a structure that signals deep mutual confidence in the technology's potential.

The CNS Conundrum: A Barrier Built by Nature

The central nervous system is the body's most protected organ system, shielded by the highly selective blood-brain barrier. This dense network of cells acts as a biological fortress, meticulously controlling which substances pass from the bloodstream into the brain. While this defense is critical for protecting the brain from toxins and pathogens, it also blocks nearly all large-molecule drugs and over 95% of small-molecule drugs from reaching their intended targets.

For decades, this has been the central challenge in neurology. Promising therapeutic candidates for conditions ranging from brain tumors to neurodegenerative diseases have failed because they simply couldn't get where they needed to go. Current methods to bypass the BBB are often fraught with risk and limitations. Invasive approaches like direct intracerebral injection carry risks of infection and provide only localized drug distribution. Other strategies, such as temporarily disrupting the barrier with focused ultrasound, are non-specific and risk damaging delicate brain tissue.

This is the problem the Nona-Lonza collaboration is designed to solve. By developing a 'molecular Trojan horse,' they aim to create a safe and efficient shuttle system that can escort a wide range of therapies across the barrier, heralding a new era of possibility for a market projected to exceed $180 billion by the end of the decade.

A Tale of Two Platforms

At the heart of the collaboration is Nona Biosciences' proprietary Harbour Mice® platform, specifically its ability to generate heavy chain-only antibodies (HCAbs). Unlike conventional antibodies, which have a large, Y-shaped structure, HCAbs are smaller and simpler. The key component is the variable domain (a VHH binder, or single-domain antibody), which is a fraction of the size of a traditional antibody but retains high specificity and binding affinity.

Their minuscule size is their superpower, theoretically enabling them to navigate the tight junctions of the BBB more effectively. Furthermore, because the Harbour Mice® platform generates fully human antibodies, the risk of triggering an immune response in patients is significantly reduced. Nona has further sharpened its edge by integrating an AI-driven discovery platform, Hu-mAtrIx™, to accelerate the identification and optimization of these antibody candidates.

Dr. Di Hong, Chief Executive Officer of Nona Biosciences, highlighted the platform's power, stating, "This collaboration underscores the power and versatility of our HCAb Harbour Mice® platform and its ability to generate differentiated, fully human single-domain binders that can tackle the most challenging delivery barriers in drug development."

This is where Lonza enters the picture. As a global leader in contract development and manufacturing (CDMO), Lonza provides the industrial-scale expertise to turn Nona's discoveries into viable therapeutic products. Lonza will apply its world-leading GS Gene Expression System® to ensure stable, high-yield production of the antibody shuttles. Additionally, its GlycoConnect® bioconjugation technology, acquired through the 2023 purchase of Synaffix, will be crucial. This technology allows for the precise, stable attachment of therapeutic payloads—be it an enzyme, an ADC toxin, or an mRNA sequence—to the antibody shuttle, ensuring the therapy remains intact until it reaches its target.

A Strategic Symbiosis for Market Dominance

The partnership is a textbook example of strategic symbiosis. For Nona, a subsidiary of HBM Holdings, it provides crucial validation of its platform and a clear pathway to commercialization. Partnering with Lonza de-risks the complex and capital-intensive manufacturing process, allowing Nona to focus on its core strength: discovery.

"Lonza's global reach, regulatory expertise, and commercial manufacturing capabilities will help accelerate the advancement of our BBB-crossing-technology," commented Dr. Jingsong Wang, Chairman of Nona Biosciences. He added that the deal strengthens Nona's position in the CNS delivery space while creating opportunities for licensing and long-term value.

For Lonza, the collaboration is a shrewd strategic move to enhance its service offerings in one of biopharma's most challenging and lucrative fields. By securing IP rights to a next-generation BBB technology, Lonza can offer its vast customer base an integrated, end-to-end solution for CNS drug development.

Peter Droc, Lonza's Head of Licensing, explained the value proposition directly: "We are immediately enabling our customers to translate promising CNS assets into viable therapeutics. By combining this with flexible CDMO services, we allow partners to engage with us at any stage of their journey... reducing complexity and helping accelerate the path to patients."

Navigating a Crowded Field

Nona and Lonza are not entering an empty arena. The race to breach the BBB is heating up, with several major players making significant investments. Companies like Denali Therapeutics and Roche's Genentech have been pioneers, primarily focusing on using engineered antibodies to target the transferrin receptor (TfR), a natural transport channel into the brain. These approaches have multiple assets in clinical trials and represent the current leading edge.

However, the Nona-Lonza approach, centered on inherently smaller, fully human single-domain antibodies, may offer distinct advantages in terms of developability, manufacturing simplicity, and reduced immunogenicity. By creating a 'plug-and-play' shuttle that can be paired with various therapeutic modalities using Lonza's advanced conjugation technology, the partnership is building a platform, not just a single product.

Their success will ultimately be determined in the clinic, but this collaboration represents a powerful convergence of innovative discovery and industrial-scale execution. By combining their respective strengths, Nona Biosciences and Lonza are making a formidable bid to finally unlock the brain and deliver hope to millions of patients awaiting a breakthrough.